Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Special Issues
August 2016, Vol 7, No7, Special Issue: Payers' Perspectives in Oncology
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
By
Lisa A. Raedler, PhD, RPh
Drug Updates
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
On April 11, 2016, the FDA approved venetoclax (Venclexta; Janssen) tablets, a first-in-class BCL-2 inhibitor for the treatment of patients with CLL plus chromosome 17p deletion, as detected by an FDA-approved test (Vysis CLL FISH probe kit), who have received at least 1 previous therapy.
Read Article
The Challenge of Balancing Access to and Paying for New, High-Cost Cancer Therapies
By
James T. Kenney, RPh, MBA
Payer’s Perspective
,
Value Peer-spectives
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Many significant and interesting topics highlighted at ASCO 2016 are discussed in this publication, covering clinical, safety, and economic issues related to cancer therapies.
Read Article
Conference Correspondent - August 2016
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Read Article
Shorter Hypofractionated Therapy New Standard for Prostate Cancer
By
Phoebe Starr
Prostate Cancer
,
Solid Tumors
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Men with intermediate-risk prostate cancer can safely undergo radiation administered in larger fractions for 4 weeks (moderate hypofractionation) as an alternative to conventional radiation administered for 8 weeks, according to the results of a randomized, controlled, noninferiority clinical trial presented at ASCO 2016.
Read Article
Is the Glass Half Empty or Half Full? First Study Compares Robotic-Assisted Surgery and Open Radical Prostatectomy
By
Alice Goodman
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
The first randomized trial to compare robotic-assisted prostatectomy with conventional open radical prostatectomy found no meaningful differences between these techniques in urinary and sexual function or in the rate of positive surgical margins in men with localized prostate cancer in the first 12 weeks after surgery (Yaxley JW, et al.
Lancet.
2016 Jul 26. Epub ahead of print).
Read Article
Combination Immunotherapy Makes Progress in Advanced Melanoma
By
Phoebe Starr
Melanoma
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Evidence is mounting that 2 immunotherapies are better than 1 as first-line treatment of patients with advanced melanoma. A phase 3 clinical trial showed that nivolumab plus ipilimumab was superior to ipilimumab or nivolumab alone, and a phase 1 trial suggests that pembrolizumab can be safely and effectively used in combination with other drugs as first-line treatment in this setting. Both studies were presented at ASCO 2016.
Read Article
Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma
By
Wayne Kuznar
Hematologic Malignancies
,
Multiple Myeloma
,
Personalized Medicine
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Interim results from a phase 1b study indicate that the investigational monoclonal antibody isatuximab, in combination with lenalidomide and dexamethasone, achieves responses in >50% of patients with relapsed or refractory multiple myeloma, including those with disease refractory to immunomodulatory drugs (IMiDs).
Read Article
Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma
By
Wayne Kuznar
Hematologic Malignancies
,
Multiple Myeloma
,
Personalized Medicine
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Adding the recently approved daratumumab (Darzalex), a human, CD38-directed monoclonal antibody, to a standard regimen of bortezomib (Velcade) and dexamethasone improved progression-free survival (PFS) by >60% compared with the standard regimen in patients with relapsed or refractory multiple myeloma, according to Antonio Palumbo, MD, Chief of the Multiple Myeloma Unit, University of Torino, Italy.
Read Article
Refining the Use of CAR T-Cells in Patients with Acute Lymphoblastic Leukemia
By
Phoebe Starr
Hematologic Malignancies
,
Leukemia
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Chimeric antigen receptor (CAR) T-cells have saved lives in some patients with acute lymphoblastic leukemia (ALL) who had run out of other treatment options. This type of immunotherapy is making inroads in other hematologic malignancies as well, but it is still being studied in very sick patients.
Read Article
CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies
By
Wayne Kuznar
Hematologic Malignancies
,
Leukemia
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
A durable complete response was achieved in a high proportion of adults with refractory B-cell malignancies who received CD19+ chimeric antigen receptor (CAR) T-cells made up of a defined 1:1 ratio of CD8+ and CD4+ cells.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma